MOUNTAINEER Trial
MOUNTAINEER is a phase II trial for people diagnosed with metastatic HER2-positive colorectal cancer or HER2-positive disease that can’t be completely removed with surgery.
Gastric Cancer and Nutrition Booklet
This booklet was created to educate patients and caregivers on nutritional guidelines for Gastric Cancer and Gastrectomy.
A Patient’s Journey Battling Stomach Cancer
In honor of Stomach Cancer Awareness Month Martha Raymond, Executive Director of the GI Cancers Alliance, interviews Steve Melen, a Stomach Cancer survivor and patient advocate, about his story with Stomach Cancer.
Exploring Clinical Trial Participation in the New Normal of COVID-19
The GI Cancers Alliance welcomes your thoughts on clinical trial participation in the midst of COVID-19.
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) for the Treatment of Patients with Advanced Esophageal Squamous Cell Carcinoma (ESCC)
Bristol Myers Squibb today announced that Opdivo® (nivolumab) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.
Triage Cancer Webinar: Latest COVID-19 News: Work, Insurance, & Finances
This webinar, will provide up-to-the-minute information about changes to health insurance and employment, including new options for paid sick leave, paid family leave, and unemployment benefits.
Bayer and NeoGenomics Launch the Test4TRK Program
Bayer and NeoGenomics launch the Test4TRK™ Program to provide genomic cancer testing at no cost for people living with advanced thyroid and colorectal cancers.
Introducing Ina, The Intelligent Nutrition Assistant from Savor Health
Personalized, evidence-based nutrition support available 24/7 “on demand” to help cancer patients stay well-nourished and manage nutrition-related treatment side effects.
COVID-19 Clinical Oncology FAQ
We understand that during this time of uncertainty due to the COVID-19 Coronavirus pandemic, the gastrointestinal cancer community has many questions and concerns.
FDA approval of Opdivo + Yervoy for patients with hepatocellular carcinoma (HCC)
Bristol Myers Squibb Company today announced that Opdivo (nivolumab) 1 mg/kg plus Yervoy (ipilimumab) 3 mg/kg (injections for intravenous use) was approved by the U.S.